My understanding is that there are multiple pathways anthracyclines target that produce cardiotoxicity, from mitochondrial direct to indirect. We really need to know what the cardio MoA for Bisantrene is so that our targets can be a little more real. If Bis MoA was targeting a similar pathway in Ara-C, that would be a very big de-risking event for the upcoming trial. Probably already the most derisked oncology drug on the planet.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080657/pdf/fcvm-07-00035.pdf
My understanding is that there are multiple pathways...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.41 |
Change
0.095(7.22%) |
Mkt cap ! $234.3M | |||
| Open | High | Low | Value | Volume |
| $1.32 | $1.41 | $1.32 | $249.8K | 182.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2826 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.43 | 40000 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.37 |
Change
0.095 ( 6.64 %) |
||||
| Open | High | Low | Volume | ||
| $1.34 | $1.41 | $1.32 | 16145 | ||
| Last updated 15.53pm 10/05/2024 ? | |||||
| RAC (ASX) Chart |